{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:30:09Z","timestamp":1778873409772,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Neurofibromatosis type 2 (NF2), an inherited disorder associated with multiple inherited schwannomas, meningiomas and ependymomas is caused by an autosomal dominant, likely loss of function germline mutation of the <jats:italic toggle=\"yes\">NF2<\/jats:italic> gene. Interestingly, biallelic <jats:italic toggle=\"yes\">NF2<\/jats:italic> gene inactivation is one of the most common mutations associated with the development of malignant mesothelioma (MM), a highly fatal malignancy that arises in the pleura and less frequently in the pericardium, peritoneum, and tunica vaginalis. It has been proposed that NF2 patients could potentially be at increased risk of developing MM. However, patients with inherited NF2 rarely develop MM. To date, only 2 cases describing patients diagnosed with both have been reported in the literature. Here, we describe the third case and for the first time, also provide molecular evidence that a \u201csecond hit\u201d involving a somatic mutation is likely required to trigger the development of MM in this rare cohort. In our patient diagnosed with NF2 at age 25 who developed an aggressive peritoneal MM 15 years later, we identified a germline <jats:italic toggle=\"yes\">NF2<\/jats:italic> mutation and somatic mutations including <jats:italic toggle=\"yes\">BAP1<\/jats:italic>. Of clinical relevance, our case supports a germline <jats:italic toggle=\"yes\">NF2<\/jats:italic> mutation may not necessarily be more susceptible to develop mesothelioma without a \u201csecond hit\u201d mutation.<\/jats:p>","DOI":"10.1097\/pas.0000000000001359","type":"journal-article","created":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T21:26:36Z","timestamp":1569187596000},"page":"288-292","source":"Crossref","is-referenced-by-count":13,"title":["Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma"],"prefix":"10.1097","volume":"44","author":[{"given":"Carolyn","family":"Glass","sequence":"first","affiliation":[{"name":"Department of Pathology, Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Landgraf","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anderson Hospital, Maryville, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucian","family":"Chirieac","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Roggli","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jmg.29.12.841","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nn.3348","article-title":"Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy","volume":"16","author":"Schulz","year":"2013","journal-title":"Nat Neurosci"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10689-005-0659-8","article-title":"Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation","volume":"4","author":"Baser","year":"2005","journal-title":"Fam Cancer"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1212\/WNL.59.2.290","article-title":"Neurofibromatosis 2 and malignant mesothelioma","volume":"59","author":"Baser","year":"2002","journal-title":"Neurology"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41379-018-0127-2","article-title":"Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42","volume":"32","author":"Stevers","year":"2019","journal-title":"Mod Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12881-018-0651-4","article-title":"First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications","volume":"19","author":"L\u00f6ffler","year":"2018","journal-title":"BMC Med Genet"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","volume":"17","author":"Borczuk","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R21-20230922","first-page":"2331","article-title":"Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12885-019-5984-7","volume":"19","author":"Casula","year":"2019","journal-title":"BMC Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:56:51Z","timestamp":1695423411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001359","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,20]]}}}